These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 19581280

  • 21. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM, Pan N, Lehman TJ, Adams A, Kalliolias GD, Zhu YS, Santiago F, Nguyen J, Sitaras L, Cunningham-Rundles S, Walsh TJ, Toussi SS.
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [Abstract] [Full Text] [Related]

  • 22. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
    Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G.
    Rheumatology (Oxford); 2012 Aug; 51(8):1407-15. PubMed ID: 22447885
    [Abstract] [Full Text] [Related]

  • 23. Etanercept in methotrexate-resistant JIA-related uveitis.
    Saeed MU, Raza SH, Goyal S, Cleary G, Newman WD, Chandna A.
    Semin Ophthalmol; 2014 Jan; 29(1):1-3. PubMed ID: 24175644
    [Abstract] [Full Text] [Related]

  • 24. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 25. Etanercept in systemic juvenile idiopathic arthritis.
    Russo RA, Katsicas MM, Zelazko M.
    Clin Exp Rheumatol; 2002 Apr; 20(5):723-6. PubMed ID: 12412209
    [Abstract] [Full Text] [Related]

  • 26. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
    Yeh KW, Lee CM, Chang CJ, Lin YJ, Huang JL.
    PLoS One; 2014 Apr; 9(6):e90757. PubMed ID: 24603504
    [Abstract] [Full Text] [Related]

  • 27. Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.
    Berard RA, Laxer RM.
    Expert Opin Biol Ther; 2013 Nov; 13(11):1623-30. PubMed ID: 24070010
    [Abstract] [Full Text] [Related]

  • 28. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
    Gudbrandsdottir S, Larsen R, Sørensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Müller K.
    Clin Exp Rheumatol; 2004 Nov; 22(1):118-24. PubMed ID: 15005015
    [Abstract] [Full Text] [Related]

  • 29. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR, British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Rheumatology (Oxford); 2015 Jul; 54(7):1279-85. PubMed ID: 25638806
    [Abstract] [Full Text] [Related]

  • 30. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
    Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F.
    Clin Exp Rheumatol; 2010 Jul; 28(6):919-22. PubMed ID: 21205467
    [Abstract] [Full Text] [Related]

  • 31. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study.
    Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, Saad-Magalhães C, Murray KJ, Bae SC, Joos R, Foeldvari I, Duarte-Salazar C, Wulffraat N, Lahdenne P, Dolezalova P, de Inocencio J, Kanakoudi-Tsakalidou F, Hofer M, Nikishina I, Ozdogan H, Hashkes PJ, Landgraf JM, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organization (PRINTO).
    Arthritis Rheum; 2007 Feb 15; 57(1):35-43. PubMed ID: 17266064
    [Abstract] [Full Text] [Related]

  • 32. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
    Tarkiainen M, Tynjälä P, Vähäsalo P, Kröger L, Aalto K, Lahdenne P.
    Pediatr Rheumatol Online J; 2019 Dec 16; 17(1):80. PubMed ID: 31842940
    [Abstract] [Full Text] [Related]

  • 33. Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.
    Tse SM, Laxer RM, Babyn PS, Doria AS.
    J Rheumatol; 2006 Jun 16; 33(6):1186-8. PubMed ID: 16755667
    [Abstract] [Full Text] [Related]

  • 34. Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.
    Mori M, Sugiyama N, Morishima Y, Sugiyama N, Kokubo T, Takei S, Yokota S.
    Mod Rheumatol; 2018 Jan 16; 28(1):101-107. PubMed ID: 28448193
    [Abstract] [Full Text] [Related]

  • 35. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Apr 16; 52(4):712-7. PubMed ID: 23267169
    [Abstract] [Full Text] [Related]

  • 36. Etanercept treatment for children with refractory juvenile idiopathic arthritis.
    Kuo HC, Yu HR, Wu CC, Chang LS, Yang KD.
    J Microbiol Immunol Infect; 2011 Feb 16; 44(1):52-6. PubMed ID: 21531353
    [Abstract] [Full Text] [Related]

  • 37. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
    Otten MH, Prince FH, Twilt M, van Rossum MA, Armbrust W, Hoppenreijs EP, Kamphuis S, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Ten Cate R, van Suijlekom-Smit LW.
    J Rheumatol; 2010 Mar 16; 37(3):665-7. PubMed ID: 20080910
    [Abstract] [Full Text] [Related]

  • 38. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE, França IL, Ribeiro AC, Sallum AM, Bonfa E, Silva CA.
    Vaccine; 2015 Jan 29; 33(5):604-9. PubMed ID: 25554240
    [Abstract] [Full Text] [Related]

  • 39. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.
    J Rheumatol; 2010 Jun 29; 37(6):1221-7. PubMed ID: 20395648
    [Abstract] [Full Text] [Related]

  • 40. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
    Katsicas MM, Russo RA.
    Clin Exp Rheumatol; 2005 Jun 29; 23(4):545-8. PubMed ID: 16095128
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.